Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
Phase 2
Active, not recruiting
NCT03964727
| Condition | Metastatic Solid Tumor |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Gilead Sciences |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 227 participants |
|---|
| Interventions | Sacituzumab Govitecan-hziy |
|---|
| Start date | Oct 15, 2019 |
|---|
| Completion date | Jan 15, 2025 |
|---|
| Results posted | Jan 30, 2026 |
|---|
Summary
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years · percentage of participants
| Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | 12.9 percentage of participants |
|---|
| Cohort 1 Group 2: NSCLC (Adenocarcinoma) | 5.9 percentage of participants |
|---|
| Cohort 1 Group 3: NSCLC (SCC) | 6.5 percentage of participants |
|---|
| Cohort 2: HNSCC | 16.3 percentage of participants |
|---|
| Cohort 3: EC | 26.8 percentage of participants |
|---|
| Cohort 4: ES-SCLC | 44.2 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.